A new experimental vaccine for pancreatic cancer has delivered positive initial findings by stimulating robust immune system activity in individuals with a high genetic predisposition. During a phase 1 clinical trial, the vaccine proved to be safe while targeting KRAS mutations prior to the onset of the disease. Further, more extensive research is required to verify if the treatment can effectively stop pancreatic cancer from occurring.

by shortkt.com✓

6 घंटे पहले